Journal Home
Search for

Volume 76, Issue 2, Pages 515.e8-515.e14 (August 2010)


View previous. 98 of 104 View next.

Expression of cAMP-dependent Protein Kinase Isoforms in the Human Prostate: Functional Significance and Relation to PDE4

Eginhard Waldkircha, Stefan ÜckertaCorresponding Author Informationemail address, Katja Siglb, Kristina Langnaesec, Karin Richterc, Christian G. Stiefd, Markus A. Kuczyka, Petter Hedlunde

Received 5 August 2009; accepted 16 April 2010. published online 05 July 2010.

Objectives

To investigate the expression of isoforms of the cyclic AMP (cAMP)–dependent protein kinase (cAK) in the transition zone of the human prostate and the functional significance of the enzyme in the control of prostate smooth muscle.

Methods

Using Western blot analysis and immunohistochemistry, the expression and distribution in the prostate of cAKIα, cAKIβ, cAKIIα, and cAKIIβ in relation to α-actin and the phosphodiesterase PDE4 (types A and B) were investigated. The effects of the cAK inhibitor Rp-8-CPT-cAMPS on the reversion of the adrenergic tension of isolated prostate tissue induced by forskolin, rolipram, sodium nitroprusside (SNP), and tadalafil were examined by means of the organ bath technique.

Results

Immunosignals specific for cAKIα, cAKIIα, and cAKIIβ were observed in the smooth musculature and glandular structures of the prostate. Double stainings revealed the colocalization of α-actin and PDE4 with the cAK isoforms. The expression of the cAK isoforms was confirmed by Western blot analysis. The relaxation of the tension induced by norepinephrine brought about by forskolin, rolipram, SNP, and tadalafil was significantly attenuated by Rp-8-CPT-cAMPS.

Conclusions

The colocalization of smooth muscle α-actin and PDE4 with cAK, as well as the results from the organ bath experiments, provide further evidence for a pivotal role of the cAMP-dependent signaling in the regulation of prostate smooth muscle contractility. Compounds interacting with the cAMP/cAK pathway might represent a new therapeutic avenue to treat symptoms of benign prostatic hyperplasia and lower urinary tract symptomatology.

a Hannover Medical School, Department of Urology and Uro-Oncology, Hannover, Germany

b MorphoSys AG, Martinsried, Germany

c Otto-von-Guericke-University, Faculty of Medicine, Institute for Biochemistry and Cell Biology, Magdeburg, Germany

d Ludwig-Maximilians-University, Academic Hospital Grosshadern, Department of Urology, Munich, Germany

e University Vita San Raffaele, Faculty of Medicine, Department of Urology, Urological Research Institute, Milan, Italy

Corresponding Author InformationReprint requests: Stefan Ückert, Ph.D., Hannover Medical School, Department of Urology and Uro-Oncology, 30623 Hannover, Germany

PII: S0090-4295(10)00596-0

doi:10.1016/j.urology.2010.04.035


View previous. 98 of 104 View next.